Related references
Note: Only part of the references are listed.Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis
Abeer H. Obaid et al.
Neurology-Neuroimmunology & Neuroinflammation (2022)
Complement Activation Is a Prominent Feature of MOGAD
Christian W. Keller et al.
ANNALS OF NEUROLOGY (2021)
International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
Pushpa Narayanaswami et al.
NEUROLOGY (2021)
The ambiguous role of mannose-binding lectin (MBL) in human immunity
Namarta Kalia et al.
OPEN MEDICINE (2021)
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
James F. Howard et al.
JAMA NEUROLOGY (2020)
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Renato Mantegazza et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
Florencia Aguirre et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Srikanth Muppidi et al.
MUSCLE & NERVE (2019)
Myasthenia gravis
Nils Erik Gilhus et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis
Linda L. Kusner et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Diagnosis and treatment of myasthenia gravis
Renato Mantegazza et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics
Maedeh Mohebnasab et al.
FRONTIERS IN IMMUNOLOGY (2019)
Interpretation of Serological Complement Biomarkers in Disease
Kristina N. Ekdahl et al.
FRONTIERS IN IMMUNOLOGY (2018)
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
Renato Mantegazza et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard et al.
LANCET NEUROLOGY (2017)
Complement component C3-The Swiss Army Knife of innate immunity and host defense
Daniel Ricklin et al.
IMMUNOLOGICAL REVIEWS (2016)
Complement system part I - molecular mechanisms of activation and regulation
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
Complement associated pathogenic mechanisms in myasthenia gravis
Erdem Tuzun et al.
AUTOIMMUNITY REVIEWS (2013)
Etiology of myasthenia gravis: Innate immunity signature in pathological thymus
Paola Cavalcante et al.
AUTOIMMUNITY REVIEWS (2013)
Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation
M. Kathryn Liszewski et al.
IMMUNITY (2013)
Complement C2 siRNA mediated therapy of myasthenia gravis in mice
Ruksana Huda et al.
JOURNAL OF AUTOIMMUNITY (2013)
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
James F. Howard et al.
MUSCLE & NERVE (2013)
Recommendations for myasthenia gravis clinical trials
Michael Benatar et al.
MUSCLE & NERVE (2012)
Evaluation of Serum IgG Subclass Concentrations in Myasthenia Gravis Patients
Yudong Liu et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2011)
Properdin: Emerging Roles of a Pattern-Recognition Molecule
Claudia Kemper et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Novel Complement Inhibitor Limits Severity of Experimentally Myasthenia Gravis
Jindrich Soltys et al.
ANNALS OF NEUROLOGY (2009)
CORRELATION OF C3 LEVEL WITH SEVERITY OF GENERALIZED MYASTHENIA GRAVIS
Aidong Liu et al.
MUSCLE & NERVE (2009)
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis
Yuefang Zhou et al.
JOURNAL OF IMMUNOLOGY (2007)
Myasthenia gravis: past, present, and future
Bianca M. Conti-Fine et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The central role of the alternative complement pathway in human disease
JM Thurman et al.
JOURNAL OF IMMUNOLOGY (2006)
The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo
F Romi et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis
E Tüzün et al.
JOURNAL OF IMMUNOLOGY (2003)
Share Paper
